Phathom Pharmaceuticals Inc (PHAT) concluded trading on Thursday at a closing price of $3.36, with 5.5 million shares of worth about $18.48 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -80.67% during that period and on May 01, 2025 the price saw a loss of about -21.68%. Currently the company’s common shares owned by public are about 68.52M shares, out of which, 38.69M shares are available for trading.
Stock saw a price change of -18.45% in past 5 days and over the past one month there was a price change of -34.38%. Year-to-date (YTD), PHAT shares are showing a performance of -58.62% which decreased to -64.06% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $3.81 but also hit the highest price of $19.71 during that period. The average intraday trading volume for Phathom Pharmaceuticals Inc shares is 1.20 million. The stock is currently trading -22.18% below its 20-day simple moving average (SMA20), while that difference is down -34.03% for SMA50 and it goes to -67.05% lower than SMA200.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) currently have 68.52M outstanding shares and institutions hold larger chunk of about 60.23% of that.
The stock has a current market capitalization of $234.02M and its 3Y-monthly beta is at 0.15. It has posted earnings per share of -$5.35 in the same period. It has Quick Ratio of 4.16. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PHAT, volatility over the week remained 11.32% while standing at 12.55% over the month.
Analysts are in expectations that Phathom Pharmaceuticals Inc (PHAT) stock would likely to be making an EPS of -1.01 in the current quarter, while forecast for next quarter EPS is -0.97 and it is -1.76 for next year. For the current quarter EPS, analysts have given the company a lowest target -1.06 which is -0.99 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -1.25 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 37.57% while it is estimated to increase by 79.45% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Cantor Fitzgerald on February 14, 2025 offering an Overweight rating for the stock and assigned a target price of $23 to it. Coverage by Stifel stated Phathom Pharmaceuticals Inc (PHAT) stock as a Buy in their note to investors on May 03, 2024, suggesting a price target of $24 for the stock. On January 05, 2024, Needham Reiterated their recommendations, while on August 09, 2023, H.C. Wainwright Initiated their ratings for the stock with a price target of $28. Stock get an Outperform rating from Evercore ISI on May 11, 2023.
